Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H15NO3.ClH |
| Molecular Weight | 257.713 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=C2OCOC2=CC3=C1CN(C)CC3
InChI
InChIKey=RIRUUBOQEZYITM-UHFFFAOYSA-N
InChI=1S/C12H15NO3.ClH/c1-13-4-3-8-5-10-12(16-7-15-10)11(14-2)9(8)6-13;/h5H,3-4,6-7H2,1-2H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C12H15NO3 |
| Molecular Weight | 221.2524 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/19252340
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/19252340
Hydrocotarnine is a crystalline alkaloid, obtained from opium and also formed by the reduction of cotarnine. It is a non-narcotic opium alkaloid. Hydrocotarnine is supposed to potentiate the analgesic effect of oxycodone with unknown mechanism.
CNS Activity
Curator's Comment: The tests were performed at different time periods (5, 15, 45 and 120 min) after male and female Wistar rats were treated with seized heroin. Seized heroin contained a mixture of opiate alkaloids, including hydrocotarnine. Opiate alkaloids were quantitatively determined in brain regions known for their high concentration of µ-opiate receptors: cortex, brainstem, amygdala and basal ganglia.
Human data not available.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL340 |
18.4 µM [IC50] | ||
Target ID: CHEMBL289 |
6.63 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseCompound injection of oxycodone and hydrocotarnine is effective for cancer pain treatment |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparison of the various opiate alkaloid contaminants and their metabolites found in illicit heroin with 6-monoacetyl morphine as indicators of heroin ingestion. | 2006 May |
|
| [Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain]. | 2007 Dec |
Patents
Sample Use Guides
injections of oxycodone and hydrocotarnine contains 8 mg of oxycodone hydrochloride and 2 mg of hydrocotarnine hydrochloride.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 00:30:52 GMT 2023
by
admin
on
Sat Dec 16 00:30:52 GMT 2023
|
| Record UNII |
XL050231LE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5985-55-7
Created by
admin on Sat Dec 16 00:30:52 GMT 2023 , Edited by admin on Sat Dec 16 00:30:52 GMT 2023
|
PRIMARY | |||
|
656658
Created by
admin on Sat Dec 16 00:30:52 GMT 2023 , Edited by admin on Sat Dec 16 00:30:52 GMT 2023
|
PRIMARY | |||
|
DTXSID50208574
Created by
admin on Sat Dec 16 00:30:52 GMT 2023 , Edited by admin on Sat Dec 16 00:30:52 GMT 2023
|
PRIMARY | |||
|
XL050231LE
Created by
admin on Sat Dec 16 00:30:52 GMT 2023 , Edited by admin on Sat Dec 16 00:30:52 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
|
PARENT -> SALT/SOLVATE |
